Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) hit a new 52-week high during trading on Monday . The company traded as high as $17.17 and last traded at $17.07, with a volume of 230,480 shares changing hands. The stock had previously closed at $16.78.

A number of analysts have recently commented on AKBA shares. Zacks Investment Research upgraded shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Aegis reaffirmed a “buy” rating and issued a $25.00 price target on shares of Akebia Therapeutics in a research report on Thursday, May 18th. ValuEngine raised Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub raised Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 16th. Finally, HC Wainwright lowered their price target on Akebia Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Monday, July 10th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $20.29.

The firm has a 50-day moving average price of $14.84 and a 200 day moving average price of $12.72. The firm’s market capitalization is $312.91 million.

Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.36. The business had revenue of $28.52 million during the quarter, compared to analyst estimates of $26.50 million. On average, equities research analysts forecast that Akebia Therapeutics, Inc. will post ($2.82) earnings per share for the current year.

In other news, Director Muneer A. Satter acquired 1,034,482 shares of Akebia Therapeutics stock in a transaction dated Wednesday, July 5th. The stock was purchased at an average cost of $14.50 per share, for a total transaction of $14,999,989.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Michel Dahan sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $15.00, for a total value of $75,000.00. Following the completion of the transaction, the senior vice president now owns 102,224 shares of the company’s stock, valued at $1,533,360. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 7,544 shares of company stock valued at $111,287. Company insiders own 8.67% of the company’s stock.

Several large investors have recently made changes to their positions in AKBA. RA Capital Management LLC purchased a new position in shares of Akebia Therapeutics in the second quarter worth about $12,018,000. Farallon Capital Management LLC purchased a new position in shares of Akebia Therapeutics in the second quarter worth about $10,490,000. Marshall Wace North America L.P. purchased a new position in shares of Akebia Therapeutics in the first quarter worth about $6,232,000. MARSHALL WACE ASIA Ltd purchased a new position in shares of Akebia Therapeutics in the first quarter worth about $6,232,000. Finally, Renaissance Technologies LLC raised its stake in shares of Akebia Therapeutics by 165.4% in the second quarter. Renaissance Technologies LLC now owns 1,025,300 shares of the biopharmaceutical company’s stock worth $14,734,000 after purchasing an additional 639,033 shares during the last quarter. Hedge funds and other institutional investors own 57.62% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Akebia Therapeutics, Inc. (AKBA) Hits New 1-Year High at $17.17” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/09/11/akebia-therapeutics-inc-akba-hits-new-1-year-high-at-17-17.html.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Receive News & Stock Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related stocks with our FREE daily email newsletter.